Thalassemia in Iran: Epidemiology, prevention, and management

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 4, 2007, Pages 233-238

  Abolghasemi, Hassan ^a,b   Amid, Ali ^a   Zeinali, Sirous ^c   Radfar, Mohammad H ^a   Eshghi, Peyman ^a,d   Rahiminejad, Mohammad S ^a,e   Ehsani, Mohammad A ^a,e   Najmabadi, Hossein ^f   Akbari, Mohammad T ^g   Afrasiabi, Abdolreza ^h   Akhavan Niaki, Haleh ⁱ   Hoorfar, Hamid ^a  

^a Iranian Pediatric Hematology and Oncology Society   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f Genetic Research Center   (Iran)

^g TARBIAT MODARES UNIVERSITY   (Iran)

^h SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ Amirkola Children's Hospital Babol   (Iran)

Author keywords

Epidemiology; Prenatal diagnosis; Prevention; Thalassemia; Treatment

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD; CONTROLLED STUDY; DISEASE REGISTRY; DRUG INDUSTRY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MARITAL THERAPY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; THALASSEMIA;

ABORTION, INDUCED; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; IRAN; MALE; NATIONAL HEALTH PROGRAMS; PREGNANCY; PRENATAL DIAGNOSIS; PREVALENCE; REGISTRIES; THALASSEMIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 34247132166     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180437e02     Document Type: Article

References (23)

1. Galanello R, Eleftheriou A, Traeger-Synodinos J, et al. Prevention of Thalassemias and Other Haemoglobin Disorders. Cyprus: Thalassemia International Federation Publications; 2003.
2. Angastiniotis M, Modell B, Englezos P, et al. Prevention and control of haemoglobinopathies. Bull World Health Organ. 1995;73:375-386.
3. Weatherall D, Akinyanju O, Fucharoen S, et al. Inherited disorders of hemoglobin. In: Jamison DT, Breman JG, Measham AR, et al. eds. Disease Control Priorities in Developing Countries. New York: Oxford University Press; 2006:663-680.
4. Modell B, Khan M, Darlison M, et al. A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ. 2001;79:1006-1013.
5. Pouya Y. Thalassemia in Iran. In: Jonxis JHP, Dela Fresnaye JF, eds. Abnormal Haemoglobins. Oxford: Blackwell Scientific Publications; 1959:263.
6. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79:704-712.
7. Roll Back Malaria, World Health Organization, UNICEF. Annex 3: Maps. In: World Malaria Report 2005. Geneva, Switzerland: World Health Organization and UNICEF Press; 2005: 281-286.
8. Najmabadi H, Karimi-Nejad R, Sahebjam S, et al. The beta-thalassemia mutation spectrum in the Iranian population. Hemoglobin. 2001;25:285-296.
9. Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol. 1995;89:473-478.
10. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
11. Samavat A, Modell B. Iranian national thalassaemia screening programme. BMJ. 2004;329:1134-1137.
12. Eram SM, Azimifar B, Abolghasemi H, et al. The IVS-II-1 (G- > a) beta0-thalassemia mutation in cis with HbA2-Troodos [delta116 (G18)Arg- > Cys (CGC- > TGC)] causes a complex prenatal diagnosis in an Iranian family. Hemoglobin. 2005;29:289-292.
13. Cao A, Galanello R, Rosatelli MC, et al. Clinical experience of management of thalassemia: the Sardinian experience. Semin Hematol. 1996;33:66-75.
14. Cao A, Rosatelli MC, Monni G, et al. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am. 2002;29:305-328.
15. Longinotti M, Pistidda P, Oggiano L, et al. A 12-year preventive program for beta-thalassemia in Northern Sardinia. Clin Genet. 1994;46:238-243.
16. Loukopoulos D. Current status of thalassemia and the sickle cell syndromes in Greece. Semin Hematol. 1996;33:76-86.
17. Karimi M, Peyvandi F, Siboni S, et al. Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. Haemophilia. 2004;10:367-369.
18. Alebouyeh M, Moussavi F, Haddad-Deylami H, et al. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann Hematol. 2004;83:430-433.
19. Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica. 2004;89:1172-1178.
20. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27:380-385.
21. Ghavamzadeh A, Nasseri P, Eshraghian MR, et al. Prognostic factors in bone marrow transplantation for beta thalassemia major: experiences from Iran. Bone Marrow Transplant. 1998;22:1167-1169.
22. Khojasteh HN, Zakerinia M, Ramzi M, et al. Bone marrow transplantation in thalassaemia patients in Shiraz, Islamic Republic of Iran. East Mediterr Health J. 2001;7:835-837.
23. Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics. 2005;116:e818-e825.